Anxiety and depression associated with a positive prostate biopsy result: A comparative, prospective cohort study.
Anxiety
Depression
Prostate-Specific Antigen
Journal
International braz j urol : official journal of the Brazilian Society of Urology
ISSN: 1677-6119
Titre abrégé: Int Braz J Urol
Pays: Brazil
ID NLM: 101158091
Informations de publication
Date de publication:
Historique:
received:
13
11
2019
accepted:
14
01
2020
entrez:
22
8
2020
pubmed:
22
8
2020
medline:
28
1
2021
Statut:
ppublish
Résumé
To investigate the course of anxiety and depression before and after transrectal ultrasound-guided prostate biopsy (TRUS-Bx) and in the postoperative 1st month when the histopathological biopsy result was obtained. In between June 2017- January 2019, 204 patients who underwent TRUS-Bx and completed the questionnaires assessing anxiety and depression were included in the study. Questionnaires were completed immediately before the biopsy, immediately after the biopsy and at the end of the first month when the histopathological biopsy results were given. State-Trait Anxiety Inventory (STAI), Hospital Anxiety and Depression Scale (HADS) and perceived stress scale (PSS) forms were used to assess anxiety and depression. After the histopathological examination patients were divided into two groups as patients without cancer (Group 1) and with cancer (Group 2). Data was compared between the groups. PSA level was negatively correlated with STAI TX-1 scores of the patients immediately after TRUS-Bx, whereas it was positively correlated with STAI TX-1 and TX-2 30 days after the TRUS-Bx. PSA level was positively correlated with HADS-A and HADS-D scores immediately before and 30 days after TRUS-Bx. Biopsy results showed a significant difference in 30 day post-biopsy related data. STAI TX-1, STAI TX-2, HADS-A, HADS-D and PSS scores were higher in Group 2 compared with Group 1. Pre-biopsy anxiety disappeared after bx, but there was a significant increase in anxiety and depression in patients after the diagnosis of malignancy. Patients were seriously concerned about the diagnosis of prostate cancer.
Identifiants
pubmed: 32822128
doi: 10.1590/S1677-5538.IBJU.2019.0719
pii: IBJU20190719
pmc: PMC7527087
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
993-1005Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright® by the International Brazilian Journal of Urology.
Déclaration de conflit d'intérêts
None declared.
Références
BJU Int. 2014 Nov;114 Suppl 1:55-61
pubmed: 25070423
Psychooncology. 2018 Feb;27(2):500-507
pubmed: 28766309
Jpn J Clin Oncol. 2014 May;44(5):463-71
pubmed: 24643291
Gen Hosp Psychiatry. 1993 Mar;15(2):69-74
pubmed: 8472942
Asian J Urol. 2017 Jan;4(1):68-74
pubmed: 29264209
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Eur J Cancer. 2010 Nov;46(17):3095-101
pubmed: 21047592
Cancer. 1994 Jun 1;73(11):2791-802
pubmed: 8194021
J Gen Intern Med. 2006 Jul;21(7):715-21
pubmed: 16808772
Urology. 1999 Jan;53(1):161-8
pubmed: 9886606
Urology. 2004 Apr;63(4):751-6
pubmed: 15072894
Psychosomatics. 2001 May-Jun;42(3):241-6
pubmed: 11351113
Eur Urol. 2012 Jun;61(6):1115-7; discussion 1117-8
pubmed: 22326676
Br J Cancer. 2006 Apr 24;94(8):1093-8
pubmed: 16622434
J Clin Oncol. 2013 Nov 20;31(33):4235-41
pubmed: 24145343
Asian J Androl. 2014 May-Jun;16(3):415-7
pubmed: 24713833
Br J Cancer. 2010 Apr 27;102(9):1335-40
pubmed: 20372151
Int J Clin Oncol. 2017 Feb;22(1):174-180
pubmed: 27631094
Psychooncology. 2015 Jun;24(6):712-7
pubmed: 25099337
Eur Urol. 2013 Apr;63(4):597-603
pubmed: 23159452
Urology. 2018 Jul;117:31-35
pubmed: 29709434
J Natl Cancer Inst. 2007 Sep 19;99(18):1395-400
pubmed: 17848671
BMJ. 2012 Jan 09;344:d7894
pubmed: 22232535